On January 9, Fosun Foundation, together with Fosun Pharma and Henan Genuine Biotech Co., Ltd., announced that they will donate 100 million yuan worth of oral drug Azvudine to rural areas in China.

Guangzhou MyGene Medical Technology Co., Ltd. announced the completion of several hundred million yuan in Series C financing. This round of financing was led by Efung Capital, the funds will be used for R&D and product registration for the IVD products.

Roche and Pfizer have launched a collaboration in the U.S. to help those who test positive for COVID-19 find the best resources for the best possible outcomes.

In partnership with Minnesota Department of Health, Cue’s digital service offers an integrated solution to provide COVID-19 treatment options access across all populations

Agilent Technologies and Qiagen said on Monday and Tuesday respectively that they have gained US Food and Drug Administration approval of companion diagnostic assays for use with a new treatment for patients with advanced non-small cell lung cancer.

Roche’s third-quarter results have revealed a clear sign that the bumper sales boosting companies that have provided products to diagnose, treat or prevent COVID-19 since the start of the pandemic are starting to tail off.

On August 30, Merck announced that the new indication for its nine-valent human papillomavirus vaccine (brewer's yeast) (hereinafter referred to as "nine-valent HPV vaccine") has been approved by National Medical Products Administration.

The Biden administration has been planning for how to get past the crisis phase of the Covid-19 pandemic and will stop buying vaccines, treatments and tests as early as this fall, White House Covid-19 Response Coordinator Dr. Ashish Jha said on Tuesday.

A pair of new studies examines genetic variations that confer risk of developing autism spectrum disorder, providing insight into the different phenotypes associated with the disorder.

August 11, the Second Roche Pan-Tumor Precision Diagnosis and Innovation Ecology Forum was officially opened at Roche Pharma China Shanghai Campus, where participants discussed solutions for pan-tumor precision diagnosis and treatment.